Study data

Antibody distribution and ADC response in breast PDOs

Explore two breast PDO studies: antibody distribution in frozen sections, and morphology and viability after ADC treatment.

Model & sampleBreast cancer PDO with antibody/nanobody distribution imaging

Study setupAF549-labeled antibody/nanobody imaging and ADC dose conditions

AssaysBright-field, fluorescence imaging, tissue distribution and viability readouts

STUDY EVIDENCE

Breast PDO studies: distribution and ADC response

Separate breast PDO studies show frozen-section distribution and ADC morphology and viability responses.

01Frozen-section distribution

Antibody distribution in breast PDO sections

Bright-field, DAPI, AF549 and merged views show relative antibody and nanobody distribution in frozen sections.

02Post-treatment morphology

Dose-dependent morphology in two PDO models

CTRL, Group 1 and Group 2 compare two conditions of the same ADC in each PDO model.

03Dose response

ADC viability in two breast PDO models

Measured viability curves show treatment responses in two breast cancer PDO models.

Study application

Frozen-section imaging shows relative antibody and nanobody distribution. A separate ADC study adds morphology and viability curves; intact-organoid penetration can be addressed with a dedicated imaging design.

Related models and services

Explore related models and services

PROJECT DISCUSSION

Plan your ADC study

Share the target, molecular format, tumor model and the distribution, dose-response or killing endpoints you want to compare.

Plan your study See how we work ↗